Psilocybin Therapy for Depression in Parkinson's Disease

Summary

The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

Eligibility

Inclusion Criteria:

* Age 40 to 80
* Comfortable speaking and writing in English
* Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an "on" phase (time when medication/DBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect)
* Currently experiencing depressive symptoms
* Able to attend all in-person visits at UCSF as well as virtual visits
* Have a primary care provider, neurologist, or psychiatrist who is actively managing or coordinating

Exclusion Criteria:

* Psychotic symptoms involving loss of insight
* Significant cognitive impairment
* Regular use of medications that may have problematic interactions with psilocybin
* A health condition that makes this study unsafe or unfeasible, determined by study physicians

Conditions3

Interventions1

Locations1 site

Find trials near these locations

Related trials

• A Randomized Neuroimaging Trial of Psilocybin in Depression — Sunnybrook Health Sciences Centre
• Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression — University Health Network, Toronto
• PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL) — Ottawa Hospital Research Institute
• Psilocybin for Hospitalized Patients with Treatment-resistant Depression — University Hospital, Ghent
• Psilocybin for Treatment-Resistant Depression in Autism — Centre for Addiction and Mental Health
• Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence — University of Colorado, Denver
• Investigation to Understand and Optimize Psilocybin — Charles Raison
• Open-Label Psilocybin Study in Transdiagnostic Population — Yale University

Browse More Trials